Two-year multicenter, randomized, double-masked, placebo-controlled, parallel safety and efficacy study of 2% pirenzepine ophthalmic gel in children with myopia
RM Siatkowski, SA Cotter, RS Crockett, JM Miller… - Journal of American …, 2008 - Elsevier
PURPOSE: To evaluate if the safety and efficacy of the relatively selective M1-antagonist,
pirenzepine, in slowing the progression of myopia in children is sustained over a 2-year
period. METHODS: This was a multicenter, parallel-group, placebo-controlled, double-
masked, randomized clinical trial. Enrolled were children aged 8 to 12 years, with entry
spherical equivalent refractive error of− 0.75 to− 4.00 D and astigmatism≤ 1.00 D. Patients
were randomized in a 2: 1 ratio to receive 2% pirenzepine ophthalmic gel or a placebo …
pirenzepine, in slowing the progression of myopia in children is sustained over a 2-year
period. METHODS: This was a multicenter, parallel-group, placebo-controlled, double-
masked, randomized clinical trial. Enrolled were children aged 8 to 12 years, with entry
spherical equivalent refractive error of− 0.75 to− 4.00 D and astigmatism≤ 1.00 D. Patients
were randomized in a 2: 1 ratio to receive 2% pirenzepine ophthalmic gel or a placebo …